Precigen Q1 net loss $23.7M, revenue down 43%; PRGN-2012 BLA submission on track for H2 2024

PRECIGEN, INC.

2024-Q1 EPS reported -$0.10

Net loss $23.7M ($0.10 EPS) vs $22.7M; total revenue down 43% YoY to approx. $1.06M.
Cash, equivalents, and short-term investments $44.8M; evaluating financing options to strengthen balance sheet.
PRGN-2012 pivotal Phase 2 data as late-breaking oral at ASCO June 3; rolling BLA submission expected H2 2024.
Commercial readiness activities underway for potential PRGN-2012 launch in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECIGEN, INC. reported financial results for first quarter 2024.

Period: first quarter 2024
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 14, 2024, reporting its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-24-006675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.